Introduction
============

Genome editing refers to the introduction of engineered mutations into specific loci of a target genome by genome editing techniques. In general, the current genome editing methods can be divided into three categories: the first category of genome editing relies on Cre (cause recombination enzyme)/*loxP* and Flp (Flippase recombination enzyme)/*FRT* (FLP recombination target); the second category is marker-free editing by the 'pop-in/pop-out' method; and the third category of genome editing relies on nucleases that recognize specific sequences.

Cre/*loxP* originates from the P1 phage. Cre is a recombinase that recognizes a specific genomic sequence called the *loxP* site. Cre recombinase removes sequences located between *loxP* sites ([@ref-1]). Flp/*FRT* originated from a plasmid in yeast. Flp is a recombinase similar to Cre, and its recognition site is named *FRT* ([@ref-9]; [@ref-13]). The implementation of Cre/*loxP* and Flp/*FRT* technologies is generally divided into two parts. First, the marker gene with the screening function is integrated into the genome to complete the transformation of the target region, and then the resistance marker gene is excised by the recombinase. However, after each round of genetic manipulation, a *loxP* or *FRT* site is left on the genome, which is very unfavorable for the study of functional genes or multigene continuous operation.

To achieve seamless editing of the genome, the researchers chose a genetic framework with a positive screening function and a reverse screening function through two rounds of genetic manipulation. In addition, homologous recombination between the two rounds of genome editing required the expression of the exogenous *λ*-Red recombinase.

The CRISPR/Cas-mediated genome editing technology that has emerged in recent years is the third generation of endonuclease-dependent genome editing technologies. The principle is based on the mechanism of bacterial resistance to the invasion of foreign phage DNA ([@ref-17]). Compared with ZFNs and TALENs, CRISPR/Cas has the advantages of simple operation, a short operating cycle and low technical requirements for the operator. The CRISPR/Cas9 system has been successfully applied in diverse organisms including but not limited to humans ([@ref-6]), mice ([@ref-2]), zebrafish ([@ref-19]), *C. elegans* ([@ref-18]), rice ([@ref-22]), *E. coli* ([@ref-11]), and *Saccharomyces cerevisiae* ([@ref-5]), Chlamydomonas chloroplasts ([@ref-23]).

For gene editing in *E. coli*, a three-plasmid system with highly efficient recombination was developed ([@ref-16]). Subsequently, a two-plasmid system was constructed which included pCas containing the Cas9 protein and pTargetF containing the sgRNA (single guide RNA) ([@ref-12]). However, the two-plasmid system still requires two steps in the process of curing the plasmid. To facilitate operation, a single-plasmid system was constructed which included Cas9 and sgRNA on one plasmid and it could be cured in one step by a temperature-sensitive element ([@ref-26]). The CRISPR/Cas-mediated genome editing technology has been used in various articles for the purposes of deleting or replacing different virulence genes. However, we have not read any report on the editing of Escherichia coli virulence genes yet. At present, only genetic engineering model strains such as *E. coli* K12, DH5*α* and BL21 have been selected for CRISPR research. ETEC is one of the leading causes of bacterial diarrhea in humans and piglets. ETEC colonizes the intestines through the pili and then produces enterotoxin, which causes electrolyte disturbances that cause diarrhea. ETEC affects intestinal immunity through NF-*κ*B and MAPK signaling pathways ([@ref-21]). [@ref-14] studied several virulence genes of ETEC and constructed an attenuated strain with the *λ*-Red recombination system in our laboratory, but the recombination efficiency was low. Due to the complicated operation steps of three-plasmid system and the high construction cost of single-plasmid system, we selected the two-plasmid system for genetic editing in ETEC. The aim of this study was to find an efficient editing method for virulence genes located on chromosomes and in plasmids. This study paved the way for further research on virulence gene function, immune mechanism and genetically engineered vaccines of ETEC.

Material and Methods
====================

Bacterial strains, plasmids, oligonucleotides, and growth conditions
--------------------------------------------------------------------

The bacterial strains and plasmids used in this work are listed in [Table 1](#table-1){ref-type="table"}. *E. coli* Trans1-T1 was used as a cloning host. The ETEC strains of *E. coli* O141:K85, *E. coli* O142 and *E. coli* DN1502 were used in the genome engineering after the susceptibility test, especially kanamycin and spectinomycin. *E. coli* O141:K85 (CVCC197) was a porcine ETEC field-isolated strain deposited in the Chinese Veterinary Culture Collection Center. *E. coli* O142 and *E. coli* DN1502 were isolated from diarrhea claves, and their virulence were tested in our laboratory ([@ref-14]; [@ref-24]). Y-1 mouse adrenocortical cells were purchased from Shanghai Cell Bank, Chinese Academy of Sciences. Based on the gene sequence published in NCBI and the pTargetF plasmid sequence published in Addgene, primers were designed using Primer 5.0 software, and the N20 sequence was designed using online software. *E. coli* were grown in lysogeny broth (1% tryptone, 0.5% yeast extract, 1% NaCl) at 30 °C or 37 °C. Kanamycin (30 µg/mL), ampicillin (100 µg/mL), and spectinomycin (250 µg/mL) were added to the medium as appropriate. L-arabinose (1.5 mg/mL final concentration) was used for *λ*-Red induction when necessary.
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###### Strains and plasmids used in this study[^a^](#table-1fn1){ref-type="fn"}.
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  Strains and plasmids                 Characteristics                                                                     Source or reference
  ------------------------------------ ----------------------------------------------------------------------------------- ------------------------------------
  *E. coli* Trans1-T1                  F^−^*ϕ*80(*lac* Z) ΔM15 Δ*lac* X74*hsd* R(r~k~^−^, $\documentclass[12pt]{minimal}   TransGen Biotech
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  *E. coli* O141:K85                   *elt I*, *estB*, *faeG*                                                             CVCC197
  *E. coli* DN1502                     *elt II c1*                                                                         This laboratory ([@ref-14])
  *E. coli* O142                       *estA*                                                                              This laboratory ([@ref-24])
  pMD19T                               *bla*                                                                               Taraka
  pCas                                 *kan*, *Cas9*, *araC*, *Gam*, *Bet*, *Exo*, *repA101*                               Kindly provided by Pro. Yang Sheng
  pTargetF                             sgRNA, *aadA*, *pMB1*                                                               Kindly provided by Pro. Yang Sheng
  pTarget-Δ*elt I*                     *aadA*, *pMB1*, sgRNA-*elt I*, Δ*elt I* (1,173 bp)                                  This study
  pTarget-Δ*estB*                      *aadA*, *pMB1*, sgRNA-*estB*, Δ*estB* (220)                                         This study
  pTarget-Δ*elt II c1*~(400)~          *aadA*, *pMB1*, sgRNA-*elt II c1*, Δ*elt II c1*~(400)~ (1,136)                      This study
  pTarget-Δ*estA*                      *aadA*, *pMB1*, sgRNA-*estA*, Δ*estA* (221)                                         This study
  pTarget-Δ*faeG*                      *aadA*, *pMB1*, sgRNA-*faeG*, Δ*faeG* (474)                                         This study
  pTarget-Δ*estB*::*estA*              *aadA*, *pMB1*, sgRNA-*estB*, Δ*estB* (220)::*estA* (505)                           This study
  pTarget-Δ*elt II c1*^p^::*faeG*      *aadA*, *pMB1*, sgRNA-*elt II c1*, Δ*elt II c1*^p^ (477 bp)::*faeG* (234)           This study
  pTarget-Δ*faeG*:: *elt II c1*^193^   *aadA*, *pMB1*, sgRNA-*faeG*, Δ*faeG* (234):: *elt II c1*^193^(477)                 This study
  pTarget-Δ*elt II c1*~(300)~          *aadA*, *pMB1*, sgRNA-*elt II c1*, Δ*elt II c1*~(300)~ (1,136)                      This study
  pTarget-Δ*elt II c1*~(200)~          *aadA*, *pMB1*, sgRNA-*elt II c1*, Δ*elt II c1*~(200)~ (1,136)                      This study
  pTarget-Δ*elt II c1*~(100)~          *aadA*, *pMB1*, sgRNA-*elt II c1*, Δ*elt II c1*~(100)~ (1,136)                      This study
  pTarget-Δ*elt II c1*~(50)~           *aadA*, *pMB1*, sgRNA-*elt II c1*, Δ*elt II c1*~(50)~ (1,136)                       This study

**Notes.**

*bla, kan* and *aadA*, represent resistance genes of ampicillin, kanamycin and spectinomycin, respectively; sgRNA-*eltI*, sgRNA with an N20 sequence for targeting eltI gene; Δ*elt I*(1,173 bp), editing template for an 1,173-bp eltI deletion; Δ*estB* (220), editing template for a 220-bp *estB* deletion; Δ*elt II c1*~(400)~ (1,136), editing template for a 1,136-bp *elt II c1* deletion with 400-bp homology arm; Δ *estA*(221), editing template for a 221-bp *estA* deletion; Δ*faeG* (474), editing template for a 474-bp faeG deletion; Δ*estB* (220)::*estA* (505), editing template for a 220-bp *estB* deletion with a 505-bp *estA* insertion; Δ*elt II c1* (477 bp)::*faeG* (234), editing template for a 477-bp partial *elt II c1* deletion with a 234-bp faeG insertion; Δ*faeG*(234)::*elt II c1*^193^ (477), editing template for a 234-bp *faeG* deletion, with a 477-bp *elt II c1*^193^ insertion which contains the mutation of the 193rd amino acid of LT-II c1; Δ*elt II c1*~(300)~ (1,136), editing template for a 1,136-bp *elt II c1* deletion with 300-bp homology arm; Δ*elt II c1*~(200)~ (1,136), editing template for a 1,136-bp *elt II c1* deletion with 200-bp homology arm; Δ *elt II c1*~(100)~ (1,136), editing template for a 1,136-bp *elt II c1* deletion with 100-bp homology arm; Δ*elt II c1*~(50)~ (1,136), editing template for a 1,136-bp *elt II c1* deletion with 50-bp homology arm. The length of the homology arm in this article refers to the length of one side. Donor primers were used to amplify homologous arms.

Plasmid construction
--------------------

We used the plasmid constructed by Sheng Yang 's laboratory ([@ref-12]) to edit the virulence gene of ETEC. These virulence genes included type II heat-labile enterotoxin c1 subtype LT-IIc1 gene (*elt II c1*) located on the chromosome; type I heat-labile enterotoxin LT-I gene (*elt I*), type I heat-stable enterotoxin gene STa (*estA*) and type II heat-stable enterotoxin STb gene (*estB*) located on the pEnt plasmid; and FaeG subunit gene (*faeG*) of K88 fimbriae located on other plasmids. First, the homology arms were amplified using the primers pairs DonorL-F/R and DonorR-F/R to form DonorL and DonorR. 2 µL bacterial solution were used as DNA sample and subjected to PCR reactions where each reaction in 25 µL consisted of 16 µL of deionized water, 1 µL of forward primer, 1 µL of reverse primer, 2 µL 2.5mM dNTPs, 2.5 µL 6X DNA Buffer and 0.5 µL EasyTaq DNA Polymerase (TransGen, 126 Beijing, China). The PCR amplification was performed as follows: initial denaturation, 94 °C for 5 min; 30 cycles of 94 °C for 30 s, 55 °C for 30 s and 72 °C for 45 s; final polymerization 72 °C for 7 min. The PCR products were separated on 0.8% agarose gel by electrophoresis. The DNA bands were cut out of the gel and extracted using the Gel Extraction Kit (Omega, Norcross, GA, USA). Then, N20 and sgRNA fragments were amplified from pTargetF by the primer pair psgRNA-F/R. The targeted N20 was designed according to GenBank ID with the help of a website (<https://zlab.bio/guide-design-resources>).

The homologous arms with N20 and sgRNA fragments were ligated into the pMD19T (Taraka, Dalian, China) vector after overlap PCR. The ligation system contained 1 µL of pMD19T, 3 µL of DNA fragments, 5 µL of Solution I, and 1 µL of deionized water. Mixed the above reagents and left at 16 °C for 1 h. The ligation product was introduced into DH5*α*. After sequencing, the correct recombinant pMD19T was named as repMD19T. repMD19T and pTargetF were digested with *Spe* I and *Xho* I, and then the digested small fragment of repMD19T and large fragment of pTargetF were ligated overnight at 16 °C using T4 ligase. In this way, pTarget-Δ*elt I*, pTarget-Δ*estB*, pTarget-Δ*elt II c1*~(400)~, pTarget-Δ*estA* and pTarget-Δ*faeG* were constructed. pTarget-Δ*estB*::*estA* was constructed by inserting the overlap PCR fragment into *Spe* I/*Xho* I-digested pTargetF, which was amplified with primers P9/P10, P11/P41, P42/P43, and P44/P14. pTarget-Δ*elt II c1* ^p^::*faeG* was constructed by inserting the overlap PCR fragment into *Spe* I/*Xho* I-digested pTargetF, which was amplified with primers P17/P45, P46/P47, P48/P49, and P50/P51. pTarget-Δ*faeG*::*elt II c1*^193^ was constructed by inserting the overlap PCR fragment into *Spe* I/*Xho* I-digested pTargetF, which was amplified with primers P33/P45, P46/P52, and P53/P51. pTarget- Δ*elt II c1*~(300)~, pTarget-Δ*elt II c1*~(200)~, pTarget-Δ*elt II c1*~(100)~, and pTarget-Δ*elt II c1*~(50)~ was constructed by inserting various lengths of homology arm amplified with pTarget-Δ*elt II c1* as a template into *Xba* I/*Xho* I-digested pTarget-Δ*elt II c1*, respectively.

Genome editing procedure
------------------------

ETEC was used in all mutagenesis experiments. The electro competent cells of original bacterial were prepared as follow steps. One single colony of ETEC from an LB agar plate was cultured overnight in 3 mL of LB medium at 37 °C. 1 mL of overnight culture was inoculated and grown in 100 mL of LB medium at 37 °C until the optical density at 600 nm (OD~600~) reached 0.6∼0.8. Then, the cells were centrifuged at 5,000 rpm for 15 min at 4 °C and washed three times with ice-cold 10% glycerol. After the final wash, 1 mL of ice-cold 10% glycerol was added to the tube to resuspend the cells, which were dispensed into a frozen EP tube per 100 µL. pCas was introduced into the competent cells. Transformation was done by electroporation using the ECM 399 Electroporation System (BTX). Electro competent cells harboring pCas were prepared by growing a single colony in 3 mL of LB medium with 30 µg/mL kanamycin at 30 °C. One milliliter of overnight culture was inoculated and grown in 100 mL of LB medium at 30 °C. L-arabinose was added to a concentration of 1.5 mg/mL at 0.2∼0.3 of OD~600~. Then, the cells were harvested at an OD~600~ of 0.6∼0.8 by centrifugation, washed three times with ice-cold 10% glycerol, and concentrated approximately 100-fold. 100 µL of electro competent cells were mixed with 300 ng of pTarget series plasmids. Electroporation was performed in a 2-mm gap electroporation cuvette (BTX) at 2.5 kV. The electro transformed cells were suspended immediately in 1 mL of LB medium and recovered at 30 °C for 1 h, after which they were plated on LB agar containing kanamycin and spectinomycin and incubated overnight at 30 °C. A single colony was picked and inoculated into LB medium containing kanamycin and spectinomycin for the next tests. Transformants were identified by PCR and DNA sequencing.

Plasmid curing
--------------

For pTarget curing, the identified bacteria were streaked onto LB plates containing kanamycin and spectinomycin and cultured overnight at 30 °C. Then, a single colony was picked and inoculated into 3 mL of LB medium containing kanamycin and 1 mM isopropyl-*β*-D-thiogalactoside (IPTG) and cultured at 30 °C for 16 h. The culture was confirmed as cured by ensuring the sensitivity to spectinomycin (250 µg/mL) and by PCR method. For pCas curing, the identified bacteria were streaked on an LB plate containing kanamycin and cultured at 30 °C overnight. Then, a single colony was picked and placed in 3 mL nonselective LB medium and cultured at 37 °C for 16 h. The cultures were confirmed as cured by measuring their sensitivity to kanamycin (30 µg/mL) and PCR method. The gene editing theory and process are shown in [Figs. 1](#fig-1){ref-type="fig"} and [2](#fig-2){ref-type="fig"}, respectively.

![Gene editing theory.\
(A) First, the host strain to be mutagenized is transformed with pCas expressing the *λ* Red component (Exo, Bet, Gam), the Cas9 endonuclease, and tracrRNA. Next, the host strain containing pCas is transformed with pTarget series carrying donor DNA and encoding the gRNA that specifies the site of cleavage. The gRNA directs the Cas9 endonuclease to the cleavage site. (B) While the gRNA recognizes 20 bases of the target site, the Cas9 mediates bacterial DNA double strand break (DSB). DSB is repaired by *λ* Red homologous recombination.](peerj-08-8881-g001){#fig-1}

![Gene editing and plasmid curing process.\
Step I: pCas was introduced into the host cell. Step II: pTarget was introduced into the host cells harboring pCas. Step III: Targeted gene of the host cells was recombined. Step IV: pTarget was cured with IPTG and cultured recombined cells at 30 °C. Step V: pCas was cured by cultured recombined cells at 37 °C.](peerj-08-8881-g002){#fig-2}

Results
=======

Editing of the ETEC virulence gene
----------------------------------

We constructed single-gene deficient and multi-genes deficient ETEC strains. For a single gene deletion, 10% of the transformants showed the expected genotype when *elt I* was deleted from *E. coli* O141:K85 ([Table 2](#table-2){ref-type="table"}, experiment 1). The efficiency of knocking out *estB* and *faeG* from *E. coli* O141:K85 was 1.4% and 23.8%, respectively. We tested the continuous virulence gene deletion ability of this two-plasmid system in ETEC. Three virulence genes of *E. coli* O141:K85 were deleted with pTarget-Δ*elt I*, pTarget-Δ*estB*, pTarget- Δ*faeG*. Then, *E. coli* O141:K85 Δ*elt I*, *E. coli* O141:K85 Δ*elt I* Δ*estb*, and *E. coli* O141:K85 Δ*elt I* Δ*estB* Δ*faeG* were obtained ([Table 2](#table-2){ref-type="table"}, experiments 1, 3, 5). These results proved that the system can continuously edit the virulence genes of ETEC.
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###### Mutation efficiency of pCas/pTarget system.
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  Expt. no.   Targeting genome locus of sgRNA   Host cell                               Plasmid pTarget                      Length of homology arm (left, right) (bp)   Number of picked colonies /recombinant colonies   Mutation efficiency (%)
  ----------- --------------------------------- --------------------------------------- ------------------------------------ ------------------------------------------- ------------------------------------------------- -------------------------
  1           *elt I*                           *E. coli* O141:K85                      pTarget-Δ*elt I*                     137,132                                     50/2                                              4.00
  2           *estB*                            *E. coli* O141:K85                      pTarget-Δ*estB*                      167,226                                     68/1                                              1.40
  3           *estB*                            *E. coli* O141:K85 Δ*elt I*             pTarget-Δ*estB*                      167,226                                     85/15                                             17.64
  4           *faeG*                            *E. coli* O141:K85                      pTarget-Δ*faeG*                      203,202                                     21/5                                              23.80
  5           *faeG*                            *E. coli* O141:K85 Δ*elt I*Δ*estB*      pTarget-Δ*faeG*                      203,202                                     50/2                                              4.00
  6           *estB*                            *E. coli* O141:K85                      pTarget-Δ*estB*::*estA*              167,226                                     99/14                                             14.14
  7           *estA*                            *E. coli* O142                          pTarget-Δ*estA*                      112,101                                     115/9                                             7.80
  8           *elt II c1*                       *E. coli* DN1502                        pTarget-Δ*elt II c1*~(400)~          404,465                                     75/51                                             68
  9           *elt II c1*                       *E. coli* DN1502                        pTarget-Δ*elt II c1*^p^::*faeG*      309,428                                     40/36                                             90
  10          *faeG*                            *E. coli* DN1502 Δ*elt II c1*::*faeG*   pTarget-Δ*faeG*:: *elt II c1*^193^   309,428                                     20/20                                             100
  11          *elt II c1*                       *E. coli* DN1502                        pTarget-Δ*elt II c1*~(300)~          304,331                                     42/54                                             77.78
  12          *elt II c1*                       *E. coli* DN1502                        pTarget-Δ*elt II c1*~(200)~          235,202                                     26/43                                             60.47
  13          *elt II c1*                       *E. coli* DN1502                        pTarget-Δ*elt II c1*~(100)~          124,103                                     1/60                                              1.67
  14          *elt II c1*                       *E. coli* DN1502                        pTarget-Δ*elt II c1*~(50)~           49,49                                       0/19                                              0

**Notes.**

Experiments 1, *elt I* was deleted from *E. coli* O141:K85. Experiments 2, *estB* was deleted from *E. coli* O141:K85. Experiments 3, *estB* was deleted from O141:K85 Δ*elt I*. Experiments 4, *faeG* was deleted from *E. coli* O141:K85. Experiments 5, *faeG* was deleted from *E. coli* O141:K85 Δ*elt I*Δ*estB*. Experiments 6, *estA* was replaced in *estB* loci in *E. coli* O141:K85. Experiments 7, *estA* was deleted from *E. coli* O142. Experiments 8, *elt II c1* was deleted from DN1502 with 400 bp homology arm. Experiments 9--10, the codon of the 193rd amino acid (leucine) of *elt II c1* was changed from CTG to CTC. Experiments 11--14, *elt II c1* was deleted from DN1502 with different length of homology arms.

Comparing the deletion of different virulence genes, we found that the mutation rate was lower than 25% when the length of the homology arm fragment was less than 200 bp ([Table 2](#table-2){ref-type="table"}, experiments 1, 2, 4). But the mutation rate increased significantly to more than 60% when the length of the homology arm was over 300 bp ([Table 2](#table-2){ref-type="table"}, experiments 6--10). Besides gene deletion, we also carried out gene replacement. The mutation efficiency was 14.14% to replace estB with estA ([Table 2](#table-2){ref-type="table"}, experiment 6).

For point mutations, pTarget-Δ*elt II c1*::*faeG* was transformed into *E. coli* DN1502 harboring pCas to replace *elt II c1* with *faeG* to obtain *E. coli* DN1502 Δ*elt II c1*::*faeG*. We constructed pTarget-Δ*faeG*::*elt II c1*^193^ which sgRNA targeted *faeG* and contained a mutant *elt II c1* fragment. Then, pTarget-Δ*faeG*::*elt II c1*^193^ was electrotransformed into the bacteria obtained in the previous step. This changed the 193rd amino acid codon of *elt II c1* from CTG to CTC, forming a *Sac* I cleavage site (GAG^192^CTC^193^). These results proved that continuous gene editing and point mutations can be achieved ([Table 2](#table-2){ref-type="table"}, experiments 9, 10).

Since the efficiency of gene deletion ranged, there is necessary to further explore whether the size of the homologous arm was related to it. We designed the pTarget-Δ*elt II c1* series with 300 bp, 200 bp, 100 bp, 50 bp homologous arms, combined with pTarget-Δ*elt II c1*~(400)~ ([Table 2](#table-2){ref-type="table"}, experiments 8, 11--14). By comparison, the gene editing efficiency was the highest when the homology arm was approximately 300 bp. The homology arms size, deletion fragment length and recombination efficiency of the target genes are listed in [Table 2](#table-2){ref-type="table"}. Agarose gel electrophoresis of colony PCR is shown in [Fig. 3](#fig-3){ref-type="fig"}.

![Agarose gel electrophoresis of colony PCR for different genes and SacI digestion.\
(A) Identification of eltI gene knockout with primers P7/P8. Lane 1, positive control. Lane 2, Negative control. (B) Identification of estB gene knockout with primers P15/P16. Lane 1, positive control. Lane 2, Negative control. (C) Identification of faeG gene knockout with primers P39/P40. Lane 1, positive control. Lane 2, Negative control. (D) Identification of eltIIc1 gene knockout with primers P23/P24. Lane 1, positive control. (E) Identification of estA inserted into estB with primers P15/P16. Lane 1, positive control. Lane 2, Negative control. (F) Identification of estA gene knockout with primers P31/P32. Lane 1, positive control. Lane 2, Negative control. (G) Identification of faeG inserted into eltIIc1 with primers P54/P55. Lane 1, positive control. Lane 2, Negative control. (H) Identification of eltIIc1^193^ gene single base mutation with primers P54/P55. Lane 1, positive control. Lane 2, Negative control. (I) Lane 1, eltIIc1^193^ of the corrected recombinant ETEC was amplified with primers P23/P24. Lane 2, amplified fragment was digested with SacI for 3 h.](peerj-08-8881-g003){#fig-3}

Plasmid curing
--------------

For the pTarget series plasmid curing, the effects of IPTG concentration and incubation time were tested. IPTG (0.5 mM and 1 mM) was used to induce the Ptrc promoter to guide sgRNA to target the pTarget series plasmid. Then, cells were cultured at 30 °C for 8, 10, 12, 14 and 16 h. The results showed that 1 mM IPTG induction with 8 h culture made the optimal combination. The colonies on the kanamycin-containing plates grew normally, while there was no visible growth on the spectinomycin-containing plates. The pTarget series plasmids were verified to be eliminated by colony PCR with primers P68/P69. pTarget series plasmids could be cured in all of the genetically edited strains.

For the pCas plasmid curing, incubation times were tested for 8, 10, 12, 14, and 16 h. The results showed that 8 h for curing pCas was enough. The colonies grew normally on the LB plates, and there was no visible growth on the kanamycin plates, indicating that the elimination of pCas was successful. pCas could be cured in all of the genetically edited strains. Agarose gel electrophoresis of colony PCR with primers P70/P71 after plasmid curing is shown in [Fig. 4](#fig-4){ref-type="fig"}.

![Agarose gel electrophoresis of colony PCR after curing the plasmids.\
(A) Verification of eltI gene knockout and plasmid curing. (B) Verification of eltIIc1 gene knockout and plasmid curing. (C) Verification of estB gene knockout and plasmid curing. (D) Verification of estA inserted into estB and plasmid curing. (E) Verification of faeG inserted into eltIIc1 and plasmid curing. (F) Verification of eltIIc1^193^ gene single base mutation and plasmid curing. (G) Verification of faeG gene knockout and plasmid curing. (H) Verification of estA gene knockout and plasmid curing. Region 1: Verification of editing fragments after curing the plasmids. Region 2: Verification of pTarget series after curing with IPTG, using primers P68/69. Region 3: Verification of pCas after curing with temperature sensitive replicon, using primers P70/P71. The first three lanes in each region are genetically edited ETEC. The fourth is a positive control and the fifth is a negative control.](peerj-08-8881-g004){#fig-4}

Discussion
==========

The CRISPR/Cas gene operating system has made great progress in the field of eukaryotes, but it is not widely used in prokaryotes. The two-plasmid system combined the CRISPR/Cas9 system and the *λ*-Red recombination to achieve target editing in the *E. coli* genome ([@ref-12]), and the recombination efficiency was greatly improved. In this system, the temperature-sensitive plasmid pCas expressed Cas9, Exo, Bet, and Gam proteins. The last three proteins mediated homologous recombination in the *λ*-Red system. pTargetF expressed an sgRNA sequence that specifically recognized the target site. There is an IPTG-induced transcription of sgRNA on pCas, which is directed to the replicon pMB1 of pTargetF. Therefore, cas9+sgRNA cleaves pMB1 to cleave and eliminate pTargetF.

To date, model strains such as *E. coli* K12 and *E. coli* BL21 (DE3) have been employed when using CRISPR/Cas in *E. coli* for genetic manipulation. However, there have been no reports of genetic manipulation in wild-type *E. coli*. In this study, we focus on the application and efficiency of the CRISPR/Cas system in wild-type ETEC virulence genes.

This two-plasmid system introduces Red recombination technology into CRISPR. The Gam protein can inhibit the RecBCD exonuclease of the host cell from degrading exogenous linear DNA. That made linear fragment could be used as the donor DNA. In fact, we tried to use linear fragment as the donor DNA early in the experiment. But there were no expected results. In Jiang's article, linear fragment donors were less efficient than circular plasmid donors ([@ref-12]). This is consistent with the results of our actual operation. Thus, donor DNA was assembled into pTarget in this study.

We tested whether continuous gene knockout can be performed in wild-type *E. coli*. After deleting single gene *elt I*, *estB*, and *faeG* from the original *E. coli* O141:K85 respectively, we successfully deleted the three genes consecutively in the bacteria. The deletion efficiency did not change significantly. This indicated that the two-plasmid system is efficient tool for editing virulence genes of ETEC in the laboratory.

We also achieved a single base mutation in *elt II c1* in *E. coli* DN1502 by two rounds of substitutions in the same position. This changed the codon of the 193rd amino acid (leucine) of *elt II c1* from CTG to CTC where a *Sac* I restriction enzyme cutting site emerged. This operation has not been reported before our study. It proved the feasibility of continue substitution at the same position in ETEC, and improved the application of the two-plasmid system.

Because we wanted to delete the complete CDS region of the virulence gene, the size of the deletion fragment depended on the target gene itself. Some published sequences have only the CDS region or are only slightly longer than the CDS region. The size of homology arm was affected by sequence published in GenBank ([Table 3](#table-3){ref-type="table"}). To explore the effect of the length of the homology arm on the recombination efficiency, we designed 5 plasmids to knock out *elt II c1*. It was found that the longer the homology arm, the higher editing efficiency when the deletion fragment length was the same. The deletion efficiency was the highest when the length of the homology arm was approximately 300 bp. The toxicity of E. coli was significantly reduced after the virulence gene was deleted. Relevant experiments and results were shown in [Supplementary Materials](#supplemental-information){ref-type="supplementary-material"}. [@ref-4] analyzed the pAA primary transcriptome using differential RNA sequencing and provided novel insights into its virulence gene expression and regulation. A recent study showed that in patients with lung adenocarcinoma, patients with lymph node metastasis had significantly elevated expression of long non-coding RNA than patients with non-lymph node metastases. This indicated that long noncoding RNAs could be seen as candidate diagnostic and prognostic biomarkers for lung adenocarcinoma ([@ref-20]). Does the non-coding region affect the toxicity of ETEC? Is the virulence gene transcribed if the promoter is deleted? These questions are interesting and worthy of further exploration.
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###### N20 + PAM sequence and GenBank ID.

![](peerj-08-8881-g007)

  Target gene   N20+PAM                     GenBank
  ------------- --------------------------- --------------------------------------------------------------
  *elt I*       AAGCTTGGAGAGAAGAACCC TGG    [CP002732.1](http://www.ncbi.nlm.nih.gov/nuccore/CP002732.1)
  *elt II c1*   TCTTTTGGTGCGATA GAAGG GGG   [JQ031705.1](http://www.ncbi.nlm.nih.gov/nuccore/JQ031705.1)
  *estB*        CAAATAATGGTTGCAGCAAA AGG    [AY028790.1](http://www.ncbi.nlm.nih.gov/nuccore/AY028790.1)
  *faeG*        GCCGGTGTGTTCGGGAAAGG TGG    [V00292.1](http://www.ncbi.nlm.nih.gov/nuccore/V00292.1)
  *estA*        TGTTGTAATCCTGCCTGTGC TGG    [V00612.1](http://www.ncbi.nlm.nih.gov/nuccore/V00612.1)

**Notes.**

Primers for virulence genes and N20 are designed according to the GenBank ID in the table.

The *elt I*, *estA*, *estB* and *faeG* locous are located on the plasmid of *E. coli*, and the *elt II c1* loci is located on the *E. coli* chromosome. It demonstrated that the two-plasmid-based CRISPR-Cas9 system can target genes in plasmids and chromosomes, which was important to edit virulence genes in ETEC.

To identify the recombinant strain by PCR, the pair of primers on the outside of the homology arm was required. If homologous arm primers were used, it would result in false positives. Because the pTarget plasmid with the homologous arm was not eliminated at this time.

The specificity of the CRISPR/Cas9 system depends mainly on sgRNA ([@ref-3]; [@ref-8]). The designed sgRNA may form a mismatch with nontarget DNA sequences, resulting in unintended gene mutations, that are called off-target effects ([@ref-25]). The off-target mutations can cause genomic instability and disrupt the function of other normal genes ([@ref-10]; [@ref-15]). The off-target effect of Cas9 has been reported frequently in eukaryotes ([@ref-7]; [@ref-10]). When we knocked out the *estB*, the first selected colony of N20 did not complete the knockout task. Another colony of N20 was replaced to continue and then succeeded. To reduce the off-target effects of Cas9 in this study, it was best to ensure that the 12 bases at the 3′end of the N20 sequence were highly specific to the genome ([@ref-11]; [@ref-12]). Existing online sgRNA design tools are not specifically targeted at ETEC. The evaluation of sgRNA off-target probability is based on *E. coli* K12 MG1655 instead of ETEC. It might lead to inaccurate evaluation of sgRNA off-target probability. From this current experimental results, the knockout efficiency can meet our requirements for gene editing.

The two-plasmid CRISPR/Cas system gives us more convenient conditions to study ETEC. The two-plasmid CRISPR/Cas system gives us more convenient conditions to study ETEC. It could be used to explore amino acids that affected virulence through site-directed mutations. And it also could be used to display foreign proteins on outer membrane or fimbriae of ETEC to stimulate the body to produce antibodies. We believe that the two-plasmid system will be more widely adopted following the further research.

Conclusions
===========

ETEC is one of the important pathogens causing human and animal diarrhae. But the researches of its virulence genes were affected due to the lack of efficient gene editing tools. In this study, we explored the validity of the two-plasmid system of CRISPR/Cas for editing the virulence genes in ETEC. The results show that the two-plasmid system of CRISPR/Cas used in this study can edit the virulence genes on the ETEC plasmids and chromosome for deleting, replacing, and mutating. The editing efficiency is closely related to the homologous arm length, and the efficiency is the highest when the length of the homology arm is approximately 300 bp. This system can also be used for single base mutation through two rounds of replacement at the same position. These studies about how to quickly and efficiently perform gene editing in ETEC using the two-plasmid-based CRISPR-Cas9 system lay the foundation for further research on the roles of virulence genes in pathogenicity, antigenicity and adjuvanticity, and mutation of virulence genes for genetically engineering a vaccine of ETEC.

Supplemental Information
========================
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###### Primer sequences

Underline is the enzyme cleavage site, the italic is N20, and the double underline is the part of the pTarget plasmid. \*Primers are from <http://www.addgene.org/>.

###### 

Click here for additional data file.
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###### Sequencing results of recombinant genes

###### 

Click here for additional data file.
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###### Plasmids digested with SpeI and XhoI

From left to right are: pTarget, pTarget-Delt, pTarget-Δstb, pTarget-stb::estA, pTarget-ΔfaeG, pTarget-ΔestA, pTarget-ΔeltIIc1, pTarget-ΔeltIIc1::faeG, pTarget-ΔfaeG:: eltIIc1^193^

###### 

Click here for additional data file.
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###### Toxic effects of ETEC enterotoxins

###### 

Click here for additional data file.
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###### Nucleic acid electrophoresis scans

###### 

Click here for additional data file.
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